We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazilian health officials have claimed that if the government fails
to secure a deal on the compulsory licensing of patented ARVs, it may allow copies of the products in question to be imported.
Gentium S.p.A. (AMEX: GNT) (the "Company") announced that the underwriters of its initial public offering of June 16, 2005 have exercised their over-allotment option to purchase an additional 300,000 of the Company's American Depositary Shares (ADSs), at a price of $9.00.
Biota Holdings Limited announced today its Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support Biota's influenza drug, Relenza.
A pain drug development company spun out of The University of Queensland has received a $3.25 million investment commitment to develop its innovative new pain therapy.
Oxford BioMedica (LSE: OXB), the leading gene therapy company, announced today that the UK Motor Neurone Disease (MND) Association has awarded a research grant to support preclinical evaluation of MoNuDin for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease.
Singapore drug discovery firm MerLion Pharmaceuticals Pte. Ltd. said Tuesday it is extending collaboration with Merck & Co. (MRK) to discover and develop new drug candidates derived from natural products chemistry.
Tokyo-based Kirin Brewery Co. Ltd. announced Monday the acquisition of substantially all of Hematech LLC. Hematech, which has a laboratory in Sioux Falls, is a biotech vaccine company.
In an example of a push towards homegrown production of drugs for major fatal diseases in Africa, Uganda is hoping to develop a new artemisinin-based combination therapy, which has its origins in the shrub wormwood.